ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
International Journal of Medicinal Mushrooms
インパクトファクター: 1.423 5年インパクトファクター: 1.525 SJR: 0.433 SNIP: 0.661 CiteScore™: 1.38

ISSN 印刷: 1521-9437
ISSN オンライン: 1940-4344

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v11.i1.40
pages 29-37

Ethyl Acetate Extracts of Submerged Cultured Mycelium of Higher Basidiomycetes Mushrooms Inhibit Human Ovarian Cancer Cell Growth

Amal Rouhana-Toubi
Department of Evolutionary and Environmental Biology and Institute of Evolution, University of Haifa, Mount Carmel, Israel; Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel
Solomon P. Wasser
N.G. Kholodny Institute of Botany, NAS of Ukraine, 2 Tereshchenkovskaya Str., Kiev 01004, Ukraine; International Center for Cryptogamic Plants and Fungi, Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel
Fuad Fares
Department of Human Biology, Faculty of Natural Sciences, University of Haifa, Mount Carmel, Israel; Department of Molecular Genetics, Carmel Medical Center, Mount Carmel, Haifa, Israel

要約

Higher Basidiomycetes mushrooms (HBM) are a well-known source of anticancer agents, yet few works have evaluated the effectiveness of HBM metabolites against ovarian cancer. In the present study, 22 strains of HBM belonging to 19 species were grown under submerged conditions. Biomasses were dried, ground, and extracted by three different organic solvents: chloroform, ethanol, and ethyl acetate in an attempt to extract low-molecular-weight substances. These 66 extracts were screened for their effect on the viability of ovarian cancer cells (ES-2) in vitro. Four ethyl acetate extracts of Coprinus comatus, Grifola frondosa, Hypsizygus marmoreus, and Phellinus igniarius were found to be most effective, with IC50 ≤ 25 μg/mL, and were used for further evaluations. It was found that all four ethyl acetate extracts were active against other ovarian cancer cell lines: SKOV-3 and SW-626. The results indicated that the ES-2 cells revealed more anticancer activity of the extracts, in comparison to SKOV-3 and SW-626 cells. The reduction in ES-2 cell survival reached almost 100% at a concentration of 75−100 μg/mL, in all cases, whereas the reduction in SKOV-3 and SW-626 survival, at the same concentrations, was 50%−70%. All selected extracts were tested for toxicity and were nontoxic at the tested concentrations. Our results show that ethyl acetate extracts of the HBM strains studied reduced the viability of human ovarian cancer cells.


Articles with similar content:

Antiproliferative Activity of Some Higher Mushrooms from Hungary against Human Cancer Cell Lines
International Journal of Medicinal Mushrooms, Vol.17, 2015, issue 12
Attila Vanyolos, Istvan Zupko, Noemi Bozsity, Judit Hohmann, Bernadett Kovacs
Inhibitory Effect of Ethyl Acetate Extract of the Shaggy Inc Cap Medicinal Mushroom, Coprinus comatus (Higher Basidiomycetes) Fruit Bodies on Cell Growth of Human Ovarian Cancer
International Journal of Medicinal Mushrooms, Vol.15, 2013, issue 5
Abed Agbarya, Solomon P. Wasser, Amal Rouhana-Toubi, Fuad Fares
Medicinal Mushroom Extracts Possess Differential Antioxidant Activity and Cytotoxicity to Cancer Cells
International Journal of Medicinal Mushrooms, Vol.17, 2015, issue 5
Eglal AbdAllah Ghonimy, Mahomud Mohammed Alassar, Fang-Sheng Wu, Eman Nasr Elbatrawy
The Shaggy Inc Cap Medicinal Mushroom, Coprinus comatus (O.F.Mull.: Fr.) Pers. (Agaricomycetideae) Substances Interfere with H2O2 Induction of the NF-κB Pathway through Inhibition of IκBα Phosphorylation in MCF7 Breast Cancer Cells
International Journal of Medicinal Mushrooms, Vol.13, 2011, issue 1
Solomon P. Wasser, Nili Ruimi, Abraham Reznick, Mikheil D. Asatiani, Eviatar D. Nevo, Jamal A. Mahajna
The Shaggy Ink Cap Medicinal Mushroom, Coprinus comatus (Higher Basidiomycetes) Extract Induces Apoptosis in Ovarian Cancer Cells via Extrinsic and Intrinsic Apoptotic Pathways
International Journal of Medicinal Mushrooms, Vol.17, 2015, issue 12
Solomon P. Wasser, Amal Rouhana-Toubi, Fuad Fares